Fisher & Paykel Healthcare Launches New CPAP Device

Fisher & Paykel Healthcare Corporation Limited announced today the release of F&P SleepStyle™, a CPAP device used in the treatment of obstructive sleep apnea (OSA).

 

F&P SleepStyle

SleepStyle has been designed to be easy for sleep specialists and OSA patients to use. It strives to strike a balance between comfort and effective treatment by including a world-class auto algorithm with central apnea detection and a full range of innovative comfort options. Specific features include an easy-access chamber, user-friendly menu, large and responsive menu buttons, built-in connectivity options and a quiet, integrated design. Expiratory relief of CPAP pressure during exhalation is also provided to make breathing more comfortable.

The device includes the popular ThermoSmart™ humidification featuring a heated breathing tube with AirSpiral™ technology to minimise condensation, and SensAwake™, which detects wakefulness and automatically reduces treatment pressure to a comfortable level.

“Adhering to OSA treatment can be one of the most challenging aspects for patients, so the design process for SleepStyle has been about creating a product that is comfortable, effective and extremely simple and easy for people to use,” said Managing Director and Chief Executive Officer, Lewis Gradon. “SleepStyle is a quality device that complements our award-winning range of OSA masks.”

Built-in cellular and Bluetooth connectivity options ensure both patients and clinicians can receive information when required. Patients are able to track their own progress and receive trouble shooting tips using an F&P SleepStyle app, and the F&P InfoSmart™ patient management system automatically highlights patients who need their clinician’s attention.

SleepStyle will be available in New Zealand and Australia in June, and in other countries on receipt of the relevant regulatory clearances.

 

 

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Ends

 

Contact:

Investor Media
Marcus Driller
General Manager Corporate
marcus.driller@fphcare.co.nz
+64 (0) 27 578 9663
Rachel Reynolds
Senior Communications Manager
rachel.reynolds@fphcare.co.nz
+64 (0) 21 713 911

 

Attachment